Dr. Issa is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1515 Holcombe Blvd
Houston, TX 77030Phone+1 713-792-6161
Education & Training
University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2014 - 2017
Icahn School of Medicine at Mount Sinai/Beth IsraelResidency, Internal Medicine, 2011 - 2014
St Joseph's University Medical SchoolClass of 2010
Certifications & Licensure
FL State Medical License 2021 - Present
TX State Medical License 2017 - 2026
OK State Medical License 2020 - 2021- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- CPX-351 in Treating Patients With Newly Diagnosed, High-Risk Acute Myeloid Leukemia Start of enrollment: 2015 May 04
- ABL001 for the Treatment of Chronic Myeloid Leukemia in Patients Who Are on Therapy With Tyrosine Kinase Inhibitor Start of enrollment: 2020 Jul 29
Publications & Presentations
PubMed
- Clinical interrogation of TP53 aberrations and its impact on survival in patients with myeloid neoplasms.Jayastu Senapati, Sanam Loghavi, Guillermo Garcia-Manero, Guillin Tang, Tapan Kadia
Haematologica. 2024-12-12 - Impact of Measurable Residual Disease Clearance Kinetics in Patients with AML Undergoing Intensive Chemotherapy.Wei Ying Jen, Koji Sasaki, Farhad Ravandi, Tapan M Kadia, Sa A Wang
Blood Advances. 2024-12-04 - Longitudinal follow up of a phase 2 trial of venetoclax added to hyper-CVAD, nelarabine and pegylated asparaginase in patients with T-cell acute lymphoblastic leukemia...Farhad Ravandi, Jayastu Senapati, Nitin Jain, Nicholas J Short, Tapan Kadia
Leukemia. 2024-12-01
Abstracts/Posters
- Characteristics and Outcomes of Therapy-Related Versus De Novo Acute Myeloid Leukemia with Normal KaryotypeGhayas C. Issa, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- The Impact of Smoking on Survival in Patients (Pts) with Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Treated with the Com...Ghayas C. Issa, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Fludarabine, Cytarabine, G-CSF and Gemtuzumab Ozogamicin (FLAG-GO) Regimen Results in Better Molecular Response and Relapse-Free Survival in Core Binding Factor Acute ...Ghayas C. Issa, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Join now to see all
Lectures
- Identification of Gene Expression Signatures in Leukemia Stem Cells and Minimal Residual Disease Following Treatment of Adverse Risk Acute Myeloid Leukemia61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Ultrasensitive Duplex Sequencing of Pretreatment ABL1 Kinase Domain Mutations in Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leu...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) Vs. Standard Intensive Chemotherapy (hyper-CVAD) As Frontline Therapy for Older P...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
ASH: Triplet Combination Regimens Demonstrate High Response Rates in Multiple LeukemiasDecember 10th, 2024- Syndax Presents Positive Revuforj® (Revumenib) Data in Acute Leukemias from Multiple Trials, Including the SAVE Combination and AUGMENT-101 Trials, at 66th ASH Annual MeetingDecember 8th, 2024
- Syndax Pharmaceuticals Leukemia Drug Wins a First-in-Class FDA ApprovalNovember 18th, 2024
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
